NOVOZYMES, GREAT GREEN PLAY BUT WAIT (REDUCE; -9% DOWNSIDE)
20/11/20 -"Novozymes (Reduce, Denmark) is a classic example of a ‘good company at an unattractive price’. We were cautiously optimistic on this Denmark-based enzyme market leader (48% share) when we teased ..."
Pages
51
Language
English
Published on
20/11/20
You may also be interested by these reports :
05/12/25
Against the backdrop of strong execution, with two outlook upgrades in 2025, backed by vigorous growth across all its focus areas (oncology, ...
28/11/25
Novo’s investors losing more weight than its patients
25/11/25
CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...
25/11/25
Even though the sentiment around Novo has been extremely adverse (further exacerbated by today’s R&D development around Alzheimer’s), in our opinion, ...